156 related articles for article (PubMed ID: 35921529)
1. Fecal β-glucuronidase activity differs between hematopoietic cell and kidney transplantation and a possible mechanism for disparate dose requirements.
Khan MH; Onyeaghala GC; Rashidi A; Holtan SG; Khoruts A; Israni A; Jacobson PA; Staley C
Gut Microbes; 2022; 14(1):2108279. PubMed ID: 35921529
[TBL] [Abstract][Full Text] [Related]
2. Reduced Enterohepatic Recirculation of Mycophenolate and Lower Blood Concentrations Are Associated with the Stool Bacterial Microbiome after Hematopoietic Cell Transplantation.
Saqr A; Carlson B; Staley C; Rashidi A; Al-Kofahi M; Kaiser T; Holtan S; MacMillan M; Young JA; Jurdi NE; Weisdorf D; Khoruts A; Jacobson PA
Transplant Cell Ther; 2022 Jul; 28(7):372.e1-372.e9. PubMed ID: 35489611
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiota profiles and fecal beta-glucuronidase activity in kidney transplant recipients with and without post-transplant diarrhea.
Zhang LT; Westblade LF; Iqbal F; Taylor MR; Chung A; Satlin MJ; Magruder M; Edusei E; Albakry S; Botticelli B; Robertson A; Alston T; Dadhania DM; Lubetzky M; Hirota SA; Greenway SC; Lee JR
Clin Transplant; 2021 May; 35(5):e14260. PubMed ID: 33605497
[TBL] [Abstract][Full Text] [Related]
4. Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT).
Jacobson P; Huang J; Rydholm N; Tran M; Defor T; Tolar J; Orchard PJ
J Clin Pharmacol; 2008 Apr; 48(4):485-94. PubMed ID: 18296555
[TBL] [Abstract][Full Text] [Related]
5. Temporal shifts in safety and efficacy profile of mycophenolate mofetil 2 g versus 3 g daily early after heart transplantation.
Braghieri L; Jennings DL; Bohn B; Habal M; Pinsino A; Mondellini GM; Ladanyi A; Latif F; Clerkin K; Restaino S; Kurlansky P; Takeda K; Naka Y; Demmer RT; Sayer GT; Uriel N; Colombo PC; Yuzefpolskaya M
Pharmacotherapy; 2022 Sep; 42(9):697-706. PubMed ID: 35979678
[TBL] [Abstract][Full Text] [Related]
6. Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation.
Bejanyan N; Rogosheske J; Cao Q; Lazaryan A; Holtan S; Ustun C; Jacobson P; MacMillan M; Weisdorf DJ; Wagner J; Arora M; Brunstein CG
Eur J Haematol; 2021 Feb; 106(2):205-212. PubMed ID: 33084139
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
8. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.
Glander P; Hambach P; Braun KP; Fritsche L; Waiser J; Mai I; Neumayer HH; Budde K
Int J Clin Pharmacol Ther; 2003 Oct; 41(10):470-6. PubMed ID: 14703953
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin relieves mycophenolate mofetil-induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity.
Taylor MR; Flannigan KL; Rahim H; Mohamud A; Lewis IA; Hirota SA; Greenway SC
Sci Adv; 2019 Aug; 5(8):eaax2358. PubMed ID: 31457102
[TBL] [Abstract][Full Text] [Related]
10. Metagenomics combined with activity-based proteomics point to gut bacterial enzymes that reactivate mycophenolate.
Simpson JB; Sekela JJ; Graboski AL; Borlandelli VB; Bivins MM; Barker NK; Sorgen AA; Mordant AL; Johnson RL; Bhatt AP; Fodor AA; Herring LE; Overkleeft H; Lee JR; Redinbo MR
Gut Microbes; 2022; 14(1):2107289. PubMed ID: 35953888
[TBL] [Abstract][Full Text] [Related]
11. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
12. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
[TBL] [Abstract][Full Text] [Related]
13. Limits to intensified mycophenolate mofetil dosing in kidney transplantation.
Kiberd BA; Lawen J; Daley C
Ther Drug Monit; 2012 Dec; 34(6):736-8. PubMed ID: 23007746
[TBL] [Abstract][Full Text] [Related]
14. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.
Zucker K; Rosen A; Tsaroucha A; de Faria L; Roth D; Ciancio G; Esquenazi V; Burke G; Tzakis A; Miller J
Transpl Immunol; 1997 Sep; 5(3):225-32. PubMed ID: 9402690
[TBL] [Abstract][Full Text] [Related]
15. Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates.
Machka C; Lange S; Werner J; Wacke R; Killian D; Knueppel A; Knuebel G; Vogel H; Lindner I; Roolf C; Murua Escobar H; Junghanss C
Biol Blood Marrow Transplant; 2014 Sep; 20(9):1301-6. PubMed ID: 24923538
[TBL] [Abstract][Full Text] [Related]
16. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients.
van Hest RM; Doorduijn JK; de Winter BC; Cornelissen JJ; Vulto AG; Oellerich M; Löwenberg B; Mathot RA; Armstrong VW; van Gelder T
Ther Drug Monit; 2007 Jun; 29(3):353-60. PubMed ID: 17529894
[TBL] [Abstract][Full Text] [Related]
18. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Hamilton BK; Liu Y; Hemmer MT; Majhail N; Ringden O; Kim D; Costa L; Stuart R; Alousi A; Pidala JA; Couriel DR; Aljurf M; Antin JH; Bredeson C; Cahn JY; Cairo M; Choi SW; Dandoy C; Gale RP; Gergis U; Hematti P; Inamoto Y; Kamble RT; MacMillan M; Marks DI; Nemecek E; Nishihori T; Saad A; Savani BN; Schriber J; Seo S; Socié G; Teshima T; Verdonck LF; Waller EK; Wirk M; Spellman SR; Arora M; Chhabra S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1744-1755. PubMed ID: 31158502
[TBL] [Abstract][Full Text] [Related]
19. A study comparing mycophenolate mofetil to azathioprine in simultaneous pancreas-kidney transplantation.
Odorico JS; Pirsch JD; Knechtle SJ; D'Alessandro AM; Sollinger HW
Transplantation; 1998 Dec; 66(12):1751-9. PubMed ID: 9884272
[TBL] [Abstract][Full Text] [Related]
20. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
